Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

INTERVENTIONALInicio: 5 de may de 2025ID: NCT06988670

ReclutandoFase 2ClinicalTrials.gov

A Phase II, Randomized, Open-label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients With Multiple Sclerosis

INTERVENTIONALInicio: 13 de nov de 2025ID: NCT07074886

ReclutandoFase 2ClinicalTrials.gov

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)

INTERVENTIONALInicio: 10 de feb de 2026ID: NCT07215702

ReclutandoFase 3ClinicalTrials.gov

IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment

INTERVENTIONALInicio: 30 de sept de 2025ID: NCT07106762

ReclutandoFase 3ClinicalTrials.gov

A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis

INTERVENTIONALInicio: 21 de oct de 2022ID: NCT05485961

ReclutandoFase 2ClinicalTrials.gov

A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

INTERVENTIONALInicio: 7 de nov de 2023ID: NCT06122779

ReclutandoClinicalTrials.gov

Regional Assessment of the Risk of Lung Injury in Ventilated Patients With Similar Lung Load

OBSERVATIONALInicio: 1 de dic de 2023ID: NCT06486259

ReclutandoFase 3ClinicalTrials.gov

EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease

INTERVENTIONALInicio: 9 de may de 2025ID: NCT07064473

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)

INTERVENTIONALInicio: 11 de jun de 2025ID: NCT06951698

ReclutandoFase 4ClinicalTrials.gov

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

INTERVENTIONALInicio: 28 de dic de 2017ID: NCT03340506

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze

INTERVENTIONALInicio: 3 de ene de 2024ID: NCT06191315

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

INTERVENTIONALInicio: 4 de mar de 2022ID: NCT05215340

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

INTERVENTIONALInicio: 1 de oct de 2025ID: NCT07196748

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

INTERVENTIONALInicio: 1 de dic de 2023ID: NCT06215716

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

INTERVENTIONALInicio: 23 de oct de 2025ID: NCT07076121

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

INTERVENTIONALInicio: 1 de ago de 2023ID: NCT05855200

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

INTERVENTIONALInicio: 26 de sept de 2024ID: NCT06585787

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis

INTERVENTIONALInicio: 2 de oct de 2023ID: NCT05609630

ReclutandoFase 3ClinicalTrials.gov

IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

INTERVENTIONALInicio: 11 de sept de 2025ID: NCT06926868

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

INTERVENTIONALInicio: 22 de may de 2025ID: NCT06952504